Philadelphia, PANCT07501663Now EnrollingIRB Ready

Peripheral Neuropathy Clinical Trial in Philadelphia, PA

Access cutting-edge peripheral neuropathy treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access peripheral neuropathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related peripheral neuropathy treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this peripheral neuropathy clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Peripheral Neuropathy Study in Philadelphia

The objective of the proposed pilot is to test the feasibility, acceptability, and preliminary efficacy of a 16-week sequential, multiple assessment randomized trial (SMART), which includes virtual Tai Chi/Qi Gong or α- Lipoic acid (ALA) supplements as an initial treatment, and acupuncture as the additional treatment, that examines a stepped-care intervention to address CIPN.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Who Can Participate

Inclusion Criteria

Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study:
Age 18 years or older,
Self-reported moderate (≥ 2/4) numbness and tingling on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Numbness and Tingling Severity Item in the previous week,
At least three months since the last receipt of neurotoxic chemotherapy,
Prior receipt of paclitaxel, docetaxel, cisplatin, oxaliplatin, nab-paclitaxel, or carboplatin for the treatment of stage I-III Gastrointestinal (GI) cancers,
Speaking/reading English.

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:
Prognosis of ≤ 3 months,
Documented neuropathy attributed to other causes (e.g., diabetic neuropathy),
Intention to initiate a new prescription of duloxetine or other pain medications (i.e., first-line treatment for CIPN pain) during the study period; however, participants may continue on duloxetine or other pain medications if initiated at least 8 weeks before study enrollment, with no change in dose, and reporting unmanaged CIPN (i.e., ≥ 2/4) PRO-CTCAE numbness/tingling severity in the last week,
Currently using alcohol (ethyl), which means regular alcohol consumption (defined as ≥7 drinks/week for women, ≥14 drinks/week for men, or binge drinking \>3 drinks per occasion at least weekly) within the past 3 months, or current alcohol use disorder or inability/unwillingness to abstain from alcohol during the study intervention period,
Currently using calcium salts, iron preparations or magnesium salts orally,
With thyroid disorders, particularly those with hypo- or hyperthyroidism,
With thiamine deficiency, as assessed and verified by the physician.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT07501663) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Peripheral Neuropathy Treatment Options in Philadelphia, PA

If you're searching for peripheral neuropathy treatment options in Philadelphia, PA, this clinical trial (NCT07501663) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced peripheral neuropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all peripheral neuropathy clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Philadelphia, PA

See all pulmonary embolism clinical trials recruiting in Philadelphia — not just this study.

Browse Pulmonary Embolism Trials in Philadelphia →

Browse More Trials by Condition

Pulmonary Embolism TrialsNeuropathy TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA